Axitinib

Name: Axitinib | 319460-85-0
Brand: US-CATO
SKU: S57C4X-1071_100_MG
Price: 19998.0 USD
Availability: InStock

Cat. No S57C4X-1071_100_MG

Vendor: US-CATO

Product Information

Product Name

Axitinib

Brand Name

US-CATO

Product Number

C4X-1071

CAS

319460-85-0

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

6450551

IUPAC Name

N-methyl-2-3-(E)-2-pyridin-2-ylethenyl-1H-indazol-6-ylsulfanylbenzamide

InChI Key

RITAVMQDGBJQJZ-FMIVXFBMSA-N

SMILES

CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4

References Data Source From Pubchem

Microbiome modulation in cancer immunotherapy

Publication Name: Nature Medicine

Publication Date: 2026-03-09

DOI: 10.1038/s41591-026-04285-x

Implications of the molecular toxicity and cytocompatibility by the nano-caged C60 in MCF-7 breast cancer cells: an in vitro study

Publication Name: Naunyn-Schmiedeberg's Archives of Pharmacology

Publication Date: 2026-03-02

DOI: 10.1007/s00210-026-05147-6

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; pembrolizumab for head and neck cancer, tucatinib for breast cancer, and trametinib for ovarian cancer

Publication Name: International Journal of Clinical Oncology

Publication Date: 2026-02-28

DOI: 10.1007/s10147-026-02994-4

Avelumab/Axitinib

Publication Name: Reactions Weekly

Publication Date: 2026-02-28

DOI: 10.1007/s40278-026-92755-1

A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium

Publication Name: Cancer immunology, immunotherapy : CII

Publication Date: 2026-02-25

DOI: 10.1007/s00262-025-04288-6

Axitinib

Product Information

General Information

References Data Source From Pubchem

Microbiome modulation in cancer immunotherapy

Implications of the molecular toxicity and cytocompatibility by the nano-caged C60 in MCF-7 breast cancer cells: an in vitro study

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; pembrolizumab for head and neck cancer, tucatinib for breast cancer, and trametinib for ovarian cancer

Avelumab/Axitinib

A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium

Axitinib

Mycophenolate Mofetil EP Impurity H

Mycophenolate Mofetil

Flurbiprofen Impurity 21 (Mixture of Diastereomers)

Docetaxel Impurity 40

H-Met-Glu-OH

Fluticasone Impurity 106

Efavirenz Related Compound C

Cholecalciferol EP Impurity A

About Us

Popular Searches

Contact

#title#

Features
Availability:
Price
Options
Actions

Axitinib

Product Information

General Information

References Data Source From Pubchem

Microbiome modulation in cancer immunotherapy

Implications of the molecular toxicity and cytocompatibility by the nano-caged C60 in MCF-7 breast cancer cells: an in vitro study

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; pembrolizumab for head and neck cancer, tucatinib for breast cancer, and trametinib for ovarian cancer

Avelumab/Axitinib

A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium

Axitinib

Related Product

Mycophenolate Mofetil EP Impurity H

Mycophenolate Mofetil

Flurbiprofen Impurity 21 (Mixture of Diastereomers)

Docetaxel Impurity 40

H-Met-Glu-OH

Fluticasone Impurity 106

Efavirenz Related Compound C

Cholecalciferol EP Impurity A

#title#

Login

Register